The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2025 | Lower-risk MDS: improving outcomes with luspatercept, imetelstat & new agents
In this video, Valeria Santini, MD, University of Florence, Florence, Italy, gives an overview of recent advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), with a focus on therapies for anemia. She highlights findings from the COMMANDS trial (NCT03682536) of luspatercept, which has been shown to improve patient survival and transfusion independence. Prof. Santini also discusses data on imetelstat, which has shown durable responses and potential disease-modifying activity in patients with high transfusion burden. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
